Interim Report January – September 2023
Business Highlights during the third quarter 2023 · Encouraging preclinical data using uTREAT[®] in non-small cell lung cancer · Positive Phase II data reported from uTRACE[®] in brain cancer · Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress Copenhagen, Denmark, 23 November 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for the period January 1 – September 30, 2023. The interim report is available as an attached file to this release and on the Company’s website.